BioCryst Pharmaceuticals (BCRX) CCO reports equity holdings details
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
BioCryst Pharmaceuticals' Chief Commercial Officer, Ronald Dullinger, has filed an initial Form 3 reporting his equity holdings in the company. As of 01/01/2026, he beneficially owns 258,372 shares of common stock, which include 206,813 restricted stock units that vest in four equal annual installments starting on each grant’s anniversary.
He also holds several employee stock options to purchase common stock, including grants for 100,000 shares at $2.85 per share expiring in 2029 and 100,000 shares at $8.31 per share expiring in 2030. Additional option awards cover smaller blocks of shares at exercise prices between $6.43 and $11.43, with expiration dates running through 2035. Each option grant vests 25% per year over four years from its grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Dullinger Ronald
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Emp. Stock Option (Right to Buy) | -- | -- | -- |
| holding | Emp. Stock Option (Right to Buy) | -- | -- | -- |
| holding | Emp. Stock Option (Right to Buy) | -- | -- | -- |
| holding | Emp. Stock Option (Right to Buy) | -- | -- | -- |
| holding | Emp. Stock Option (Right to Buy) | -- | -- | -- |
| holding | Emp. Stock Option (Right to Buy) | -- | -- | -- |
| holding | Emp. Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Emp. Stock Option (Right to Buy) — 100,000 shares (Direct);
Common Stock — 258,372 shares (Direct)
Footnotes (1)
- Includes 206,813 restricted stock units which vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on November 29, 2019. Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 15, 2020. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2021. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2022. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2023. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2024. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 17, 2025.
FAQ
What does the BioCryst (BCRX) Form 3 filing report for Ronald Dullinger?
The Form 3 reports that Chief Commercial Officer Ronald Dullinger has disclosed his initial beneficial ownership in BioCryst Pharmaceuticals common stock and employee stock options as of 01/01/2026.
What stock options are reported for Ronald Dullinger in the BioCryst Form 3?
He holds multiple employee stock options (rights to buy) BioCryst common stock, including grants for 100,000 shares at $2.85 per share expiring in 2029 and 100,000 shares at $8.31 per share expiring in 2030, plus additional grants at higher prices with later expirations.
How do Ronald Dullinger’s BioCryst stock options vest?
Each annual employee option grant becomes exercisable at a rate of 25% on each of the first, second, third, and fourth anniversaries of its grant date, as described in the footnotes.
Are Ronald Dullinger’s BioCryst holdings direct or indirect?
The Form 3 indicates that both his common stock and his employee stock options are held with direct (D) ownership, with no separate entity listed for indirect ownership.
What is the purpose of this BioCryst (BCRX) Form 3 filing?
This Form 3 serves as an initial statement of beneficial ownership for officer Ronald Dullinger, disclosing his BioCryst common stock, restricted stock units, and stock option awards as required for company insiders.